Sleep
Melatonin and Sleep: What the Science Actually Says
Most people take melatonin at ten times the dose the research supports — and wonder why it stops working. The clinical literature tells a more nuanced story: melatonin is a circadian timing signal, not a sedative, and its effectiveness depends heavily on dose, timing, and what your cortisol is doing at 10 p.m.

What Melatonin Actually Does in the Brain
Melatonin is a hormone synthesized primarily by the pineal gland in response to darkness. Its core job is not to sedate you — it is to signal to every cell in your body that night has arrived. When light fades, the suprachiasmatic nucleus (SCN) releases its inhibition on the pineal gland, melatonin rises, core body temperature drops, and sleep pressure mounts. The hormone binds to MT1 and MT2 receptors in the SCN to reinforce circadian phase and promote sleep onset (Zisapel, Journal of Neural Transmission 2018; PMID: 29397481).
This distinction matters enormously for how you use it. Because melatonin is a timing cue rather than a sedative, taking 10 mg an hour before bed is not ten times more effective than taking 0.5 mg — it may actually blunt your receptors' sensitivity over time. A landmark dose-finding study by Lewy et al. found that physiological doses as low as 0.3–0.5 mg were sufficient to shift circadian phase, while doses above 1 mg produced supraphysiological blood levels that extend well into the daytime hours (Lewy et al., Sleep Medicine Reviews 2007; PMID: 17408953). Their crossover design tested doses from 0.3 mg to 10 mg across 32 participants and found no additional phase-shifting benefit beyond 0.5 mg — meaning the 5 mg and 10 mg doses commonly sold in the U.S. are, for most healthy adults, pharmacological rather than physiological.
Timing is as important as dose. The dim-light melatonin onset (DLMO) — the point at which endogenous melatonin begins to rise in the evening — typically occurs 2 hours before habitual sleep time. Taking supplemental melatonin at or just before DLMO produces the largest phase advance. Taking it too late (immediately at bedtime) or too early (mid-afternoon, unless treating advanced sleep phase) reduces effectiveness substantially. For most healthy adults struggling with sleep onset, the evidence supports starting at 0.5–1 mg taken 30–60 minutes before the desired sleep time. Higher doses may still be appropriate for specific populations — jet lag, shift work, or delayed sleep phase disorder — but that is a different clinical use case.
How Melatonin Interacts With Stress and Cortisol
One of the most underappreciated reasons melatonin does not work for people is an elevated evening cortisol level. Cortisol and melatonin are functionally antagonistic: healthy circadian rhythm involves cortisol peaking in the morning and melatonin peaking at night. When chronic stress keeps the HPA axis activated into the evening, cortisol suppresses melatonin secretion, delays sleep onset, and fragments sleep architecture — particularly slow-wave and REM stages.
A landmark paper by Buckley and Schatzberg documented that HPA dysregulation was strongly associated with insomnia characterized by difficulty initiating sleep and early-morning awakening, with evening cortisol levels inversely correlated with slow-wave sleep percentage (Buckley & Schatzberg, Journal of Clinical Endocrinology & Metabolism 2005; PMID: 15741256). If your cortisol is high at 10 p.m., supplemental melatonin is fighting upstream biology. In practice, this means people with the most refractory insomnia often have the worst response to melatonin supplementation — not because melatonin doesn't work, but because the cortisol signal is drowning it out.
Addressing adrenal rhythm — through stress management, light hygiene, and in some cases adaptogenic support — often does more for sleep quality than adding more melatonin. This is also why sleep and stress are inseparable topics. Deep sleep recovery after chronic stress is a nuanced process that often requires addressing both the HPA axis and sleep architecture simultaneously, not just adding a supplement.
Glycine for Sleep: A Surprisingly Powerful Amino Acid
Glycine is the smallest amino acid and one of the most underrated sleep compounds in the clinical literature. It is not a melatonin substitute — it works through entirely different mechanisms — but the evidence for it as a sleep quality enhancer is compelling.
In a double-blind, crossover trial published in Sleep and Biological Rhythms, 11 participants who took 3 g of glycine before bed reported significantly reduced subjective sleepiness the following morning and demonstrated improvements in polysomnographic measures of sleep efficiency and sleep latency (Bannai et al., Sleep and Biological Rhythms 2012; PMID: 23329110). A follow-up study from the same group found that 3 g of glycine before sleep in sleep-restricted participants (defined as sleeping 25% less than their habitual duration) reduced daytime fatigue and improved psychomotor vigilance task scores the next day — suggesting that glycine partially offsets the cognitive cost of insufficient sleep (Bannai & Kawai, Sleep Medicine Reviews 2012; PMID: 22738658).
The proposed mechanisms are threefold: glycine acts as an inhibitory neurotransmitter in the brainstem; it lowers core body temperature by dilating peripheral blood vessels (mimicking one of melatonin's key physiological effects); and it modulates NMDA receptor activity in the hypothalamus to reduce arousal drive. The core body temperature effect is particularly interesting — a 0.3–0.5°C drop in core temperature in the first third of the night is strongly associated with deeper NREM sleep, and glycine appears to accelerate this drop without pharmacological sedation.
Critically, glycine does not cause morning grogginess, does not impair daytime alertness, and is well tolerated at the clinical dose of 3 g. For people who can fall asleep but wake frequently during the night — a pattern often associated with elevated cortisol or low blood sugar — glycine's temperature-lowering and inhibitory effects may specifically help maintain consolidated sleep.
Magnolia Bark for Sleep: The Cortisol-Sleep Connection
Magnolia bark extract (Magnolia officinalis) contains two primary bioactive compounds: honokiol and magnolol. Honokiol in particular has drawn scientific interest for its ability to interact with GABA-A receptors — the same receptors targeted by benzodiazepines — but without the dependency risk or the architecture-disrupting effects associated with pharmaceutical sedatives.
A preclinical study demonstrated that honokiol reduced sleep latency and increased NREM sleep time by acting as a positive allosteric modulator of GABA-A receptors containing the α1 subunit (Chen et al., Phytomedicine 2012). Crucially, unlike benzodiazepines, honokiol appears to potentiate rather than activate these receptors — meaning it requires the presence of GABA itself to exert an effect. This may explain why users report a calming rather than sedating effect, and why the risk of tolerance appears to be lower than with direct GABA agonists.
Beyond its GABAergic effects, magnolia bark also shows cortisol-lowering activity in human studies. A randomized, double-blind, placebo-controlled trial published in Nutrition Journal found that a combination of magnolia bark and phellodendron bark extract reduced salivary cortisol and self-reported stress in moderately stressed adults over 4 weeks (Kalman et al., Nutrition Journal 2008; PMID: 18426577). The evening cortisol reduction observed in that trial — roughly 18% compared to placebo — is clinically meaningful in the context of the cortisol-melatonin antagonism described earlier. Lower evening cortisol directly supports endogenous melatonin secretion, making magnolia bark an interesting complement to melatonin rather than a replacement.
Typical clinical doses in human trials range from 200–400 mg of standardized extract (containing ≥1% honokiol). Because it touches the GABA system, it is worth discussing with a healthcare provider if you are taking any centrally active medications.
Saffron for Sleep: More Than a Spice
Saffron (Crocus sativus) is best known as an expensive culinary spice, but its bioactive compounds — crocin, crocetin, and safranal — have attracted serious attention in the psychiatric and sleep literature over the past decade.
A randomized controlled trial published in the Journal of Clinical Sleep Medicine found that 14 mg of affron® (a standardized saffron extract) taken twice daily for 28 days improved Pittsburgh Sleep Quality Index scores by 22%, reduced nocturnal awakenings by a statistically significant margin, and improved daytime mood in adults with self-reported poor sleep — without adverse effects (Lopresti et al., Journal of Clinical Sleep Medicine 2021; PMID: 33135005). The proposed mechanism involves saffron's inhibition of serotonin reuptake, which increases serotonin availability — and serotonin is the direct biochemical precursor to melatonin via the enzyme AANAT (arylalkylamine N-acetyltransferase). By increasing serotonin tone, saffron may support endogenous melatonin production rather than replacing it.
Safranal, one of the volatile compounds responsible for saffron's aroma, also shows affinity for GABA-A receptors in preclinical models, suggesting a secondary GABAergic mechanism that complements honokiol's effects. What makes saffron particularly interesting from a longevity perspective is the overlap between its mood-modulating and sleep-promoting properties. Poor sleep, low mood, and elevated inflammatory markers form a self-reinforcing cycle. By addressing serotonergic tone alongside sleep quality, saffron may interrupt this cycle at multiple points. The doses used in sleep trials — typically 14–28 mg of standardized extract — are well below the amounts associated with any adverse effects in toxicology studies.
For individuals whose sleep difficulty is closely tied to low mood, rumination, or anxiety rather than pure circadian phase disruption, saffron may be a more mechanistically appropriate first-line botanical than melatonin itself.
L-Tyrosine for Sleep: The Nuanced Picture
L-tyrosine is primarily known as a precursor to dopamine, norepinephrine, and thyroid hormones — which is precisely why its relationship with sleep is more complicated than the other compounds discussed here. L-tyrosine itself is not a sleep promoter. It is typically used for cognitive performance, stress resilience, and thyroid support, and taking it close to bedtime can be stimulating for some individuals due to catecholamine synthesis.
However, the connection to sleep is real and worth understanding. Tyrosine is also a precursor to L-DOPA and downstream to dopamine, which is required for the production of norepinephrine in the locus coeruleus — a region central to the regulation of sleep-wake transitions. Severe dopamine depletion is associated with restless legs syndrome and REM sleep behavior disorder. Additionally, thyroid hormones (which require tyrosine in their synthesis) regulate basal metabolic rate and core body temperature, both of which influence sleep quality.
A military-funded crossover trial found that 150 mg/kg of tyrosine reduced performance decrements and subjective fatigue during 24-hour sleep deprivation compared to placebo, without altering subsequent sleep architecture when assessed by polysomnography (Neri et al., Aviation, Space, and Environmental Medicine 1995). This is an important nuance: tyrosine does not appear to damage sleep structure, but it does sustain wakefulness while awake — which is why timing matters. Using it in the morning or early afternoon to buffer the cognitive and adrenal cost of a stressful day is mechanistically sensible; using it within 4–6 hours of bedtime is not.
So the L-tyrosine and sleep relationship is indirect: adequate tyrosine status supports neurotransmitter and thyroid hormone synthesis that in turn contribute to healthy sleep architecture. For people whose poor sleep is driven by afternoon energy crashes, thyroid dysfunction, or dopaminergic deficits (common in shift workers and those with high cognitive demands), addressing tyrosine status may be part of the broader picture. See also: melatonin for shift workers for a deeper look at how circadian disruption interacts with neurotransmitter balance.
Sleep, Glucose, and the Longevity Angle
Sleep quality and metabolic health are bidirectionally linked in ways that extend far beyond feeling rested. A single night of poor sleep — defined in one widely cited study as 4 hours — impaired insulin sensitivity the following morning by approximately 25% compared to 8-hour controls, mediated at least in part by elevated morning cortisol and growth hormone dysregulation (Spiegel et al., Sleep 1999; PMID: 10543671). Chronically fragmented sleep is associated with elevated fasting glucose, increased cortisol-driven gluconeogenesis, and a higher risk of type 2 diabetes independent of diet and exercise.
This means sleep optimization is not just a quality-of-life issue — it is a metabolic and longevity intervention. For those tracking fasting glucose trends, understanding what supplements affect fasting glucose alongside sleep quality gives a more complete metabolic picture. And for shift workers or anyone with disrupted sleep schedules, how often fasting glucose should be tested becomes a genuinely important question, since metabolic variance is higher when sleep is inconsistent.
What This Means for Your Formula
Ones does not currently stock melatonin as a standalone ingredient — and that is a deliberate choice. Because melatonin is a hormone with dose-sensitive and timing-sensitive effects, it sits in a different regulatory and clinical category than most micronutrients and botanicals. What Ones does offer is a set of complementary pathways that support melatonin's natural production and the downstream conditions required for deep, restorative sleep.
Ones' Adrenal Support blend is formulated to address HPA axis dysregulation — the cortisol-melatonin antagonism described earlier. By supporting adrenal rhythm, it helps clear the physiological resistance that blunts melatonin's effects in chronically stressed individuals.
Ashwagandha (KSM-66, 600 mg) in the Ones catalog is one of the most rigorously studied adaptogenic ingredients for stress and sleep. A double-blind RCT in Cureus found that KSM-66 at 600 mg daily for 12 weeks significantly improved sleep quality (Pittsburgh Sleep Quality Index score improved by 72% vs. 29% in placebo), sleep onset latency, and sleep efficiency in adults with stress and anxiety (Langade et al., Cureus 2019; PMID: 31728244). This is the precise dose Ones uses — not an underdosed proprietary blend.
Magnesium Glycinate (included in Ones' Magnesium Complex) addresses two mechanisms simultaneously: glycine's direct sleep-promoting effects described above, and magnesium's role in GABA receptor function and the regulation of the HPA axis. Magnesium deficiency is associated with elevated evening cortisol and hyperarousal — both enemies of sleep onset. A randomized trial in elderly adults found that 500 mg of magnesium daily for 8 weeks improved sleep efficiency, sleep time, and early-morning awakening compared to placebo, alongside reductions in serum cortisol (Abbasi et al., Journal of Research in Medical Sciences 2012; PMID: 23853635).
If your bloodwork or wearable data reveals patterns consistent with poor sleep quality, Ones' AI practitioner will analyze those signals alongside your cortisol proxies, inflammatory markers, and thyroid data to build a formula that targets the actual upstream cause — not just the symptom of lying awake.
Key Takeaways
- Melatonin is a circadian timing signal, not a sedative. Doses of 0.5–1 mg are often as effective as 5–10 mg for sleep onset — and far less likely to produce supraphysiological blood levels that extend into daytime.
- High evening cortisol is one of the most common reasons melatonin supplementation underperforms. Addressing HPA axis function through adaptogens and light hygiene often matters more than the melatonin dose itself.
- Glycine at 3 g before bed improves sleep efficiency and reduces next-day sleepiness through core temperature lowering and inhibitory neurotransmission — without morning grogginess.
- Magnolia bark extract (200–400 mg) modulates GABA-A receptors and reduces evening cortisol by roughly 18% in controlled trials, making it a useful complement to melatonin rather than a standalone sleep aid.
- Saffron standardized extract (14–28 mg) improves sleep quality and mood through serotonergic mechanisms, particularly in adults with stress-related sleep disruption, and may also support endogenous melatonin production via increased serotonin availability.
- L-tyrosine supports sleep indirectly by maintaining neurotransmitter and thyroid hormone synthesis — timing matters, and daytime use is generally more appropriate than bedtime use given its catecholamine-stimulating properties.
- Sleep quality is a metabolic variable. Consistently poor sleep disrupts glucose regulation and accelerates inflammatory aging — making sleep optimization a genuine longevity strategy, not merely a comfort issue.